ClinicalTrials.gg
Not yet recruitingNCT07918443Volido PASUpdated Nov 5, 2026

Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VI

An interventional study of Crosslinked hyaluronic acid dermal filler with lidocaine in Moderate to Severe Midface Volume Deficit, sponsored by Croma-Pharma GmbH. Not yet recruiting. Open to participants aged 22 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Croma-Pharma GmbH · Not applicable, Interventional, and Treatment

Updated Nov 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to further characterize the safety profile of saypha® ChIQ™ for midface augmentation in adults with Fitzpatrick Skin Types V and VI who have moderate to severe midface volume deficit.

The main questions it aims to answer are whether treatment with saypha® ChIQ™ has an acceptable safety profile, as assessed by the incidence and nature of treatment-emergent adverse events, including adverse device effects, injection site reactions, symptoms of interest, and ocular safety findings through 24 weeks after the last injection, and whether treatment improves midface volume deficit and subject-reported aesthetic outcomes in this study population.

Participants will receive treatment with saypha® ChIQ™ at baseline, with an optional touch-up treatment approximately 2 weeks later if clinically indicated, attend scheduled follow-up visits for safety and effectiveness assessments for up to 24 weeks after the last injection; and complete subject-reported outcome assessments and safety diaries as specified in the protocol.

Read the detailed description

saypha® ChIQ™ is an FDA-approved hyaluronic acid dermal filler indicated for cheek augmentation to correct midface volume deficit in adults. In the pivotal clinical study supporting approval, enrollment of subjects with Fitzpatrick Skin Types (FST) V and VI was below the targeted representation. Therefore, this post-approval study is being conducted in response to an FDA post-approval requirement to further characterize the safety profile of saypha® ChIQ™ in this population.

This is a prospective, multicenter, open-label, single-arm post-approval clinical trial conducted in the US. Approximately 45 adults with Fitzpatrick Skin Types V and VI and moderate to severe midface volume deficit will be enrolled and followed for 24 weeks after the last injection. The study will collect additional safety data in this underrepresented population while also evaluating treatment effectiveness using validated clinician- and subject-reported outcome measures.

02

Conditions studied

  • Moderate to Severe Midface Volume Deficit

Keywords

  • Midface Augmentation
  • Hyaluronic Acid Dermal Filler
  • saypha® ChIQ™
  • Fitzpatrick Skin Type V and VI
  • Medical Device
  • Post-Approval Study
03

In context

Lead sponsor

Croma-Pharma GmbH is the lead sponsor of 26 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 22 to 75 years of age.
  • Fitzpatrick Skin Type V or VI, as assessed by the investigator and confirmed by a central reviewer.
  • Bilateral, approximately symmetric moderate to severe midface volume deficit (score of 2 or 3 on the 5-point Midface Volume Deficit Severity Scale [MVDSS]).
  • Females of must have a negative urine pregnancy test and agree to use effective throughout the study. Male participants with female partners of childbearing potential must agree to use effective contraception throughout the study.
  • Healthy skin in the treatment area without conditions that could interfere with study assessments.
  • Willing to refrain from aesthetic or surgical procedures in the treatment area during the study, except botulinum toxin treatment of the glabella or forehead.
  • Able to understand the study, provide written , and comply with study procedures and visits.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding, or planning to become pregnant during the study.
  • History of severe allergy, anaphylaxis, or multiple severe allergies.
  • Known allergy or to hyaluronic acid, gram-positive bacterial proteins, lidocaine, or amide-type local anesthetics.
  • History of keloid formation, hypertrophic scarring, or pigment disorders.
  • Known (HIV) infection.
  • Infectious, inflammatory, malignant, or premalignant lesions in the treatment area.
  • Recurrent herpes simplex in the treatment area (three or more episodes during the previous year).
  • or connective tissue disease, or current immunomodulatory therapy.
  • Uncontrolled diabetes mellitus or other uncontrolled systemic disease considered unsuitable by the investigator.
  • Previous facial plastic surgery or treatment with permanent or long-lasting fillers in the treatment area.
  • Dermal filler treatment in the treatment area within 24 months before screening or planned during the study.
  • Aesthetic procedures in the midface area (e.g., laser therapy, threads, dermabrasion, mesotherapy, microneedling, or botulinum toxin) within 12 months before screening or planned during the study.
  • Chemical peel in the treatment area within 3 months before screening or planned during the study.
  • Facial lipolysis, including submental fat treatment, within 12 months before screening or planned during the study.
  • Bariatric surgery within 12 months before screening or planned during the study.
  • Bleeding disorder or use of anticoagulants, antiplatelet agents, thrombolytics, , nonsteroidal anti-inflammatory drugs, or other substances known to increase bleeding risk during the protocol-defined restricted period around treatment.
  • Planned dental or oral surgery within 4 weeks before or after study treatment.
  • Facial hair that may interfere with study assessments.
  • Abnormal baseline visual examination (visual acuity worse than 20/40 with correction, abnormal visual field, or abnormal ocular motility).
  • active infection within 14 days before screening.
  • Any medical condition that, in the investigator's opinion, makes participation unsuitable.
  • Previous participation in this clinical investigation or the pivotal VOLIDO study.
  • Participation in another clinical trial or treatment with an drug or medical device within 30 days before screening.
  • Midface volume deficit caused by congenital abnormalities, trauma, or abnormal facial fat distribution.
  • Weight loss of ≥10% during the previous 12 months or planned lifestyle changes expected to result in weight gain or weight loss of more than 10% during the study.
  • Individuals whose decision to participate may be subject to undue influence or coercion.
  • Employees of the sponsor or individuals with a close affiliation to the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    saypha® ChIQ™

    Participants receive treatment with saypha® ChIQ™ for correction of moderate to severe midface volume deficit. An optional touch-up treatment may be administered approximately 2 weeks after the initial treatment if clinically indicated.

    Device: Crosslinked hyaluronic acid dermal filler with lidocaine

Interventions

  • DeviceCrosslinked hyaluronic acid dermal filler with lidocaine

    saypha® ChIQ™ is an FDA-approved crosslinked hyaluronic acid dermal filler containing 23 mg/mL hyaluronic acid and 0.3% lidocaine hydrochloride. The device is administered by subcutaneous and/or supraperiosteal injection for correction of moderate to severe midface volume deficit. An optional touch-up treatment may be administered approximately 2 weeks after the initial treatment if clinically indicated.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence and nature of treatment-emergent adverse events, including adverse device effects, serious adverse events, injection site reactions, symptoms of interest, ocular safety findings, and device deficiencies following treatment with saypha® ChIQ™.

    Time frame: Baseline through Week 24 after the last injection

Secondary outcomes

  1. Injection site reactions

    Injection site reactions recorded in subject diaries during the first 4 weeks (28 days) after each treatment, assessed overall and separately for the left and right side of the midface.

    Time frame: Through 4 weeks after each treatment

  2. Subject-reported pain

    Pain following each treatment assessed using the 11-point Numeric Pain Rating Scale (NPRS).

    Time frame: Immediately after treatment through 60 minutes after each treatment

  3. Responder status on the 5-point Midface Volume Deficit Severity Scale (MVDSS) based on the evaluating investigator's live assessment

    Participants are defined as responders if they demonstrate an improvement of ≥1 point from baseline on the 5-point Midface Volume Deficit Severity Scale (MVDSS).

    Time frame: Weeks 4, 8, 16 and 24 after the last injection

  4. Responder status on the 5-point Midface Volume Deficit Severity Scale (MVDSS) based on independent photographic reviewers' assessment

    Participants are defined as responders if they demonstrate an improvement of ≥1 point from baseline on the 5-point Midface Volume Deficit Severity Scale (MVDSS), based on the assessment of standardized photographs by independent photographic reviewers.

    Time frame: Weeks 4, 8, 16, and 24 after the last injection

  5. Change from baseline in midface volume deficit measured by the 5-point Midface Volume Deficit Severity Scale (MVDSS), based on the evaluating investigator's live assessment

    Change from baseline in the 5-point Midface Volume Deficit Severity Scale (MVDSS) score, as assessed by the evaluating investigator during live evaluation. Lower MVDSS scores indicate less severe midface volume deficit.

    Time frame: Weeks 4, 8, 16, and 24 after the last injection

  6. Global aesthetic improvement based on the 5-point modified Global Aesthetic Improvement Scale (mGAIS)

    Global aesthetic improvement based on the subject's and evaluating investigator's assessment. Participants rated as "Improved" or "Much Improved" will be considered responders.

    Time frame: Weeks 4, 8, 16, and 24 after the last injection

  7. Subject satisfaction with treatment outcome and appearance based on the FACE-Q™ "Satisfaction with Outcome" and "Satisfaction with Cheeks" questionnaires

    Subject-reported satisfaction with the overall treatment outcome and satisfaction with the appearance of the cheeks, assessed using the validated FACE-Q™ "Satisfaction with Outcome" and "Satisfaction with Cheeks" questionnaires.

    Time frame: Weeks 4, 8, 16, and 24 after the last injection

  8. Injection volume required to achieve optimal aesthetic correction

    Total injection volume of saypha® ChIQ™ administered to achieve optimal aesthetic correction during the initial treatment and, if applicable, the optional touch-up treatment

    Time frame: Day 1 (initial treatment) and Week 2 (optional touch-up treatment)

  9. Change from baseline in nasolabial fold severity measured by the Nasolabial Fold Severity Rating Scale (NLF-SRS) based on the evaluating investigator's live assessment

    Change from baseline in nasolabial fold severity, as assessed by the evaluating investigator using the 5-point Nasolabial Fold Severity Rating Scale (NLF-SRS). Lower NLF-SRS scores indicate less severe nasolabial folds.

    Time frame: Weeks 4, 8, 16, and 24 after the last injection

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Nov 5, 2026
StartEst.
Jan 2027
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07918443
Lead sponsor
Croma-Pharma GmbH
Responsible party
Sponsor
First posted
Nov 5, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Head of Clinical Operation
Contact
clinical.studies@croma.at
+43 2262 684 68 0
Clinical Project Manager
Contact
clinical.studies@croma.at
+43 2262 684 68 0

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion